Senators demand more from GSK to boost Shingrix supply by Eric Sagonowsky Friday, July 6, 2018 Two U.S. senators urged GlaxoSmithKline to do more about the ongoing shortage of Shingrix.
High demand for Shingrix causes supply constraints by Eric Sagonowsky Thursday, June 21, 2018 GlaxoSmithKline's Shingrix is exceeding sales expectations, and high demand has led the company to implement order limits.
Vaccination rates, RSV vaccine and more—News of Note by Angus Liu Wednesday, June 20, 2018 Here is some other vaccine news of note for the week.
Doctors worry Shingrix side effects will put patients off their 2nd dose by Eric Sagonowsky Wednesday, June 20, 2018 Patients might be hesitant to return for their second Shingrix dose if they experience side effects, according to doctors.
GlaxoSmithKline sees some administration errors with Shingrix by Eric Sagonowsky Tuesday, June 5, 2018 In the early stages of its Shingrix rollout, GlaxoSmithKline boosted efforts to help doctors educate themselves about the vaccine.
Boosted by China launch, Merck's Gardasil turns in a big Q1 by Eric Sagonowsky Tuesday, May 8, 2018 Merck's Gardasil rollout in China helped the vaccine franchise grow sales 24% in the first quarter.
Keytruda sales stoke Merck's Q1, but where's the future growth? by Arlene Weintraub Tuesday, May 1, 2018 Merck's Keytruda ginned up $1.46 billion in the first quarter, but analysts grilled CEO Ken Frazier about his plans to deliver new backup.
Merck vaccine hopeful to battle Pfizer's Prevnar in phase 3 by Eric Sagonowsky Wednesday, April 18, 2018 Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.
